Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in human

William Harris, Carlos A. Dujovne, Klaus von Bergmann, James Neal, Jack Akester, Sheryl L. Windsor, Douglas Greene, Zee Look

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

A common pharmacologic approach to lowering elevated serum cholesterol levels has been to interfere with intestinal sterol absorption. Inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) should produce this effect. In this study, we examined the effects of CL 277,082, N-(2,4-difluorophenyl)-N-(4neopentylbenzyl) N-(n-heptyl)urea, an ACAT inhibitor, on cholesterol metabolism in humans. Eight healthy male volunteers were given a placebo for 14 days, followed by 750 mg/day CL 277,082 for 20 days in a single-blind, crossover design. Subjects were studied in a hospital research unit and were fed strictly controlled diets. Cholesterol absorption was measured by the dual isotope method during the final week of both the placebo and the drug phases. Sterol balance was also assessed during these two periods by measuring cholesterol intake, and fecal neutral and acidic sterol excretion rates. Plasma lipids and lipoproteins were measured at the end of each period. The drug was well tolerated and produced no detectable clinical or laboratory side effects. Cholesterol absorption, sterol excretion rates, and plasma lipoprotein levels were all unaffected by treatment. We conclude that CL 277,082 may not interfere with ACAT activity or cholesterol absorption in humans at the doses given under the conditions tested in this study.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume48
Issue number2
StatePublished - Aug 1990
Externally publishedYes

Fingerprint

Anticholesteremic Agents
Sterol O-Acyltransferase
Sterols
Cholesterol
Lipoproteins
Placebos
Acyl Coenzyme A
Hospital Units
Intestinal Absorption
Hypercholesterolemia
Isotopes
Pharmaceutical Preparations
Cross-Over Studies
Urea
Healthy Volunteers
Diet
Lipids
Serum
Research

ASJC Scopus subject areas

  • Pharmacology

Cite this

Harris, W., Dujovne, C. A., Bergmann, K. V., Neal, J., Akester, J., Windsor, S. L., ... Look, Z. (1990). Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in human. Clinical Pharmacology and Therapeutics, 48(2), 189-194.

Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in human. / Harris, William; Dujovne, Carlos A.; Bergmann, Klaus von; Neal, James; Akester, Jack; Windsor, Sheryl L.; Greene, Douglas; Look, Zee.

In: Clinical Pharmacology and Therapeutics, Vol. 48, No. 2, 08.1990, p. 189-194.

Research output: Contribution to journalArticle

Harris, W, Dujovne, CA, Bergmann, KV, Neal, J, Akester, J, Windsor, SL, Greene, D & Look, Z 1990, 'Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in human', Clinical Pharmacology and Therapeutics, vol. 48, no. 2, pp. 189-194.
Harris W, Dujovne CA, Bergmann KV, Neal J, Akester J, Windsor SL et al. Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in human. Clinical Pharmacology and Therapeutics. 1990 Aug;48(2):189-194.
Harris, William ; Dujovne, Carlos A. ; Bergmann, Klaus von ; Neal, James ; Akester, Jack ; Windsor, Sheryl L. ; Greene, Douglas ; Look, Zee. / Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in human. In: Clinical Pharmacology and Therapeutics. 1990 ; Vol. 48, No. 2. pp. 189-194.
@article{22f20761c8b045f0bc0440654fd3a952,
title = "Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in human",
abstract = "A common pharmacologic approach to lowering elevated serum cholesterol levels has been to interfere with intestinal sterol absorption. Inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) should produce this effect. In this study, we examined the effects of CL 277,082, N-(2,4-difluorophenyl)-N-(4neopentylbenzyl) N-(n-heptyl)urea, an ACAT inhibitor, on cholesterol metabolism in humans. Eight healthy male volunteers were given a placebo for 14 days, followed by 750 mg/day CL 277,082 for 20 days in a single-blind, crossover design. Subjects were studied in a hospital research unit and were fed strictly controlled diets. Cholesterol absorption was measured by the dual isotope method during the final week of both the placebo and the drug phases. Sterol balance was also assessed during these two periods by measuring cholesterol intake, and fecal neutral and acidic sterol excretion rates. Plasma lipids and lipoproteins were measured at the end of each period. The drug was well tolerated and produced no detectable clinical or laboratory side effects. Cholesterol absorption, sterol excretion rates, and plasma lipoprotein levels were all unaffected by treatment. We conclude that CL 277,082 may not interfere with ACAT activity or cholesterol absorption in humans at the doses given under the conditions tested in this study.",
author = "William Harris and Dujovne, {Carlos A.} and Bergmann, {Klaus von} and James Neal and Jack Akester and Windsor, {Sheryl L.} and Douglas Greene and Zee Look",
year = "1990",
month = "8",
language = "English (US)",
volume = "48",
pages = "189--194",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in human

AU - Harris, William

AU - Dujovne, Carlos A.

AU - Bergmann, Klaus von

AU - Neal, James

AU - Akester, Jack

AU - Windsor, Sheryl L.

AU - Greene, Douglas

AU - Look, Zee

PY - 1990/8

Y1 - 1990/8

N2 - A common pharmacologic approach to lowering elevated serum cholesterol levels has been to interfere with intestinal sterol absorption. Inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) should produce this effect. In this study, we examined the effects of CL 277,082, N-(2,4-difluorophenyl)-N-(4neopentylbenzyl) N-(n-heptyl)urea, an ACAT inhibitor, on cholesterol metabolism in humans. Eight healthy male volunteers were given a placebo for 14 days, followed by 750 mg/day CL 277,082 for 20 days in a single-blind, crossover design. Subjects were studied in a hospital research unit and were fed strictly controlled diets. Cholesterol absorption was measured by the dual isotope method during the final week of both the placebo and the drug phases. Sterol balance was also assessed during these two periods by measuring cholesterol intake, and fecal neutral and acidic sterol excretion rates. Plasma lipids and lipoproteins were measured at the end of each period. The drug was well tolerated and produced no detectable clinical or laboratory side effects. Cholesterol absorption, sterol excretion rates, and plasma lipoprotein levels were all unaffected by treatment. We conclude that CL 277,082 may not interfere with ACAT activity or cholesterol absorption in humans at the doses given under the conditions tested in this study.

AB - A common pharmacologic approach to lowering elevated serum cholesterol levels has been to interfere with intestinal sterol absorption. Inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) should produce this effect. In this study, we examined the effects of CL 277,082, N-(2,4-difluorophenyl)-N-(4neopentylbenzyl) N-(n-heptyl)urea, an ACAT inhibitor, on cholesterol metabolism in humans. Eight healthy male volunteers were given a placebo for 14 days, followed by 750 mg/day CL 277,082 for 20 days in a single-blind, crossover design. Subjects were studied in a hospital research unit and were fed strictly controlled diets. Cholesterol absorption was measured by the dual isotope method during the final week of both the placebo and the drug phases. Sterol balance was also assessed during these two periods by measuring cholesterol intake, and fecal neutral and acidic sterol excretion rates. Plasma lipids and lipoproteins were measured at the end of each period. The drug was well tolerated and produced no detectable clinical or laboratory side effects. Cholesterol absorption, sterol excretion rates, and plasma lipoprotein levels were all unaffected by treatment. We conclude that CL 277,082 may not interfere with ACAT activity or cholesterol absorption in humans at the doses given under the conditions tested in this study.

UR - http://www.scopus.com/inward/record.url?scp=0025183525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025183525&partnerID=8YFLogxK

M3 - Article

C2 - 2199133

AN - SCOPUS:0025183525

VL - 48

SP - 189

EP - 194

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -